About: Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® +MPL-SE® vaccine to treat canine visceral leishmaniasis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® +MPL-SE® vaccine to treat canine visceral leishmaniasis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® +MPL-SE® vaccine to treat canine visceral leishmaniasis
Creator	Mayrink, Wilson Miret, Jorge Nascimento, Evaldo Reed, Steven Sampaio, Weverton Vale, André Vieira, Edvá Fujiwara, Ricardo Campos Neto, Antonio Carlos França, João Santos Dias, Edelberto Teodoro Da Costa, Roberto
source	Elsevier; Medline; PMC
abstract	Summary The evaluation of the efficacy of an immunochemotherapy protocol to treat symptomatic dogs naturally infected with Leishmania chagasi was studied. This clinical trial had the purpose to test the combination of N-methyl meglumine antimoniate (Glucantime®) and the second generation recombinant vaccine Leish-110f® plus the adjuvant MPL-SE® to treat the canine leishmaniasis (CanL). Thirty symptomatic naturally infected mongrel dogs were divided into five groups. Animals received standard treatment with Glucantime® or treatment with Glucantime®/Leish-110f® +MPL-SE® as immunochemotherapy protocol. Additional groups received Leish-110f® +MPL-SE® only, MPL-SE® only, or placebo. Evaluation of haematological, biochemical (renal and hepatic function) and plasmatic proteins, immunological (humoral and cellular immune response) and the parasitological test revealed improvement of the clinical parameters and parasitological cure in dogs in both chemotherapy alone and immunochemotherapy cohorts. However, the immunotherapy and immunochemotherapy cohorts had reduced number of deaths, higher survival probability, and specific cellular reactivity to leishmanial antigens, in comparison with chemotherapy cohort only and control groups (adjuvant alone and placebo). These results support the notion of using well-characterized recombinant vaccine as an adjunct to improve the current chemotherapy of CanL.
has issue date	2008-03-17(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2008.01.026
bibo:pmid	18328956
has license	els-covid
sha1sum (hex)	176a9159206a6bde18152a197a946ee73d33f07f
schema:url	https://doi.org/10.1016/j.vaccine.2008.01.026
resource representing a document's title	Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® +MPL-SE® vaccine to treat canine visceral leishmaniasis
has PubMed Central identifier	PMC7127155
has PubMed identifier	18328956
schema:publication	Vaccine
resource representing a document's body	covid:176a9159206a6bde18152a197a946ee73d33f07f#body_text
is schema:about of	named entity 'meglumine' named entity 'treat' named entity 'vaccine' named entity 'N-METHYL' named entity 'CANINE VISCERAL LEISHMANIASIS' named entity 'MPL' named entity 'PROTOCOL' named entity 'RECOMBINANT' named entity 'MEGLUMINE ANTIMONIATE' named entity 'TREAT' named entity 'EVALUATION' named entity 'VACCINE' named entity 'recombinant' named entity 'visceral leishmaniasis' named entity 'canine' named entity 'peripheral blood mononuclear cells' named entity 'alopecia' named entity 'sand flies' named entity 'Concanavalin A' named entity 'adjuvant' named entity 'liver function' named entity 'clinical signs' named entity 'sodium thiopental' named entity 'chemotherapy' named entity 'phosphofructokinase' named entity 'creatinine' named entity 'parasitological' named entity 'IFAT' named entity 'antigens' named entity 'vaccine' named entity 'visceral leishmaniasis' named entity 'Glucantime' named entity 'cutaneous' named entity 'onychogryphosis' named entity 'recombinant vaccine' named entity 'endemic areas' named entity 'cytokine' named entity 'assay' named entity 'bone marrow' named entity 'protozoan' named entity 'Adenovirus' named entity 'IFAT' named entity 'L. major' named entity 'parasites' named entity 'antigens' named entity 'Acepromazine' named entity 'visceral leishmaniasis' named entity 'parasitized' named entity 'vaccine' named entity 'cut-off' named entity 'Lutzomyia longipalpis' named entity 'Amersham' named entity 'enzyme activity' named entity 'serum' named entity 'current protocols' named entity 'internal ear' named entity 'lower concentration' named entity 'saline' named entity 'Alanine' named entity 'antigens' named entity 'lipid' named entity 'prophylactic' named entity 'weight loss' named entity 'lyophilized' named entity 'pentamidine' named entity 'Bone marrow' named entity 'standard deviation' named entity 'vaccine' named entity 'immunofluorescence' named entity 'canine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software